Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - sodium fusidate -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - corynebacterium diphtheriae; neisseria meningitidis group c oligosaccharide; neisseria -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - rabies virus -

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ix 1000 [iu] (100iu/ml when reconstituted with 10ml water for injection) - injection with diluent - 1000 iu - active: factor ix 1000 [iu] (100iu/ml when reconstituted with 10ml water for injection) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) - injection with diluent - 500 iu - active: factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) - injection with diluent - 50 iu/ml - active: factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - aleviate is indicated for: ? the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 600 iu; factor viii, quantity: 250 iu - injection, diluent for - excipient ingredients: water for injections - aleviate is indicated for: ? the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 3 g - injection, solution - excipient ingredients: human immunoglobulin a; maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency (pid); * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with with recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease; * guillain-barre syndrome (gbs).

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 2400 iu; factor viii, quantity: 1000 iu - injection, powder for - excipient ingredients: sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate; albumin; sucrose; trometamol - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.